Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moonshine Ghost Train Haze is a sativa-dominant hybrid cannabis strain developed by the breeder Rare Dankness. It is a genetic cross between Moonshine Haze and Ghost Train Haze #1. Pharmacologically, the strain's therapeutic and psychoactive effects are primarily driven by a high concentration of delta-9-tetrahydrocannabinol (THC) and a specific profile of terpenes, including limonene and terpinolene. THC acts as a partial agonist at the G-protein coupled receptors Cannabinoid Receptor 1 (CB1), located primarily in the central nervous system, and Cannabinoid Receptor 2 (CB2), found predominantly in the peripheral immune system. This interaction modulates the release of various neurotransmitters, resulting in the strain's characteristic euphoric, creative, and analgesic properties. It is frequently utilized within medical cannabis programs for the management of chronic pain, mood disorders, and appetite stimulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Moonshine Ghost Train Haze.